Human hypoimmune primary pancreatic islets avoid rejection and autoimmunity and alleviate diabetes in allogeneic humanized mice
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Transplantation of allogeneic pancreatic donor islets has successfully been performed in selected patients with difficult-to-control insulin-dependent diabetes and impaired awareness of hypoglycemia (IAH). However, the required systemic immunosuppression associated with this procedure prevents this cell replacement therapy from more widespread adoption in larger patient populations. We report the editing of primary human islet cells to the hypoimmune HLA class I– and class II–negative and CD47-overexpressing phenotype and their reaggregation into human HIP pseudoislets (p-islets). Human HIP p-islets were shown to survive, engraft, and ameliorate diabetes in immunocompetent, allogeneic, diabetic humanized mice. HIP p-islet cells were further shown to avoid autoimmune killing in autologous, diabetic humanized autoimmune mice. The survival and endocrine function of HIP p-islet cells were not impaired by contamination of unedited or partially edited cells within the p-islets. HIP p-islet cells were eliminated quickly and reliably in this model using a CD47-targeting antibody, thus providing a safety strategy in case HIP cells exert toxicity in a future clinical setting. Transplantation of human HIP p-islets for which no immunosuppression is required has the potential to lead to wider adoption of this therapy and help more diabetes patients with IAH and history of severe hypoglycemic events to achieve insulin independence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Generation of Functional Human Pancreatic β Cells In Vitro
Pagliuca, F. W., Millman, J. R., Gürtler, M., Segel, M., Van Dervort, A., Ryu, J. H., Peterson, Q. P., Greiner, D., & Melton, D. A. (2014) · Cell · doi:10.1016/j.cell.2014.09.040 · Cited by 2,025
Self-citationKroon, E., Martinson, L. A., Kadoya, K., Bang, A. G., Kelly, O. G., Eliazer, S., Young, H., Richardson, M., Smart, N. G., Cunningham, J., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1393 · Cited by 1,843
Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells
Rezania, A., Bruin, J. E., Arora, P., Rubin, A., Batushansky, I., Asadi, A., O'Dwyer, S., Quiskamp, N., Mojibian, M., Albrecht, T., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.3033 · Cited by 1,575
DiMeglio, L. A., Evans-Molina, C., & Oram, R. A. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31320-5 · Cited by 1,561
Continuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
Risk of hypoglycaemia in types 1 and 2 diabetes: Effects of treatment modalities and their duration
UK Hypoglycaemia Study Group (2007) · Diabetologia · doi:10.1007/s00125-007-0599-y · Cited by 825 · cited 6×
“In addition, half of all patients with longstanding T1DM require assistance for severe hypoglycemic events, which increases their risk to that of patients with IAH (6).”
BackgroundInfluentialDeuse, T., Hu, X., Gravina, A., Wang, D., Tediashvili, G., De, C., Thayer, W. O., Wahl, A., Garcia, J. V., Reichenspurner, H., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0016-3 · Cited by 758
Self-citationClarke, W. L., Cox, D. J., Gonder-Frederick, L. A., Julian, D., Schlundt, D., & Polonsky, W. (1995) · Diabetes Care · doi:10.2337/diacare.18.4.517 · Cited by 651
Hering, B. J., Clarke, W. R., Bridges, N. D., Eggerman, T. L., Alejandro, R., Bellin, M. D., Chaloner, K., Czarniecki, C. W., Goldstein, J. S., Hunsicker, L. G., et al. (2016) · Diabetes Care · doi:10.2337/dc15-1988 · Cited by 645
Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010
Livingstone, S. J., Levin, D., Looker, H. C., Lindsay, R. S., Wild, S. H., Joss, N., Leese, G., Leslie, P., McCrimmon, R. J., Metcalfe, W., et al. (2015) · JAMA · doi:10.1001/jama.2014.16425 · Cited by 621
Cited by
Grattoni, A., Korbutt, G., Tomei, A. A., García, A. J., Pepper, A. R., Stabler, C., Brehm, M., Papas, K., Citro, A., Shirwan, H., et al. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01029-0 · Cited by 92
Self-citationSurvival of transplanted allogeneic beta cells with no immunosuppression
Carlsson, P.-O., Hu, X., Scholz, H., Ingvast, S., Lundgren, T., Scholz, T., Eriksson, O., Liss, P., Yu, D., Deuse, T., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2503822 · Cited by 84
Self-citationHu, X., White, K., Young, C., Olroyd, A. G., Kievit, P., Connolly, A. J., Deuse, T., & Schrepfer, S. (2024) · Cell Stem Cell · doi:10.1016/j.stem.2024.02.001 · Cited by 73
Self-citationProgress and challenges in developing allogeneic cell therapies
Deuse, T., & Schrepfer, S. (2025) · Cell Stem Cell · doi:10.1016/j.stem.2025.03.004 · Cited by 51
Self-citationRemyelination in the central nervous system
Franklin, R. J. M., Bodini, B., & Goldman, S. A. (2024) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a041371 · Cited by 40
Metadata
- Authors
- Hu, X., Gattis, C., Olroyd, A. G., Friera, A. M., White, K., Young, C., Basco, R., Lamba, M., Wells, F., Ankala, R., Dowdle, W. E., Lin, A., Egenberger, K., Rukstalis, J. M., Millman, J. R., Connolly, A. J., Deuse, T., & Schrepfer, S.
- Venue
- Science Translational Medicine
- Published
- 2023-04-12
- Volume
- 15
- Issue
- 691
- Pages
- eadg5794-eadg5794
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W4365139883
- Cited by
- 99
- References
- 25
- FWCI
- 23.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Human hypoimmune primary pancreatic islets avoid rejection and autoimmunity and alleviate diabetes in allogeneic humanized mice. https://app.cochat.ai/papers/10.1126/scitranslmed.adg5794
- The paper
- Hu, X., Gattis, C., Olroyd, A. G., Friera, A. M., White, K., Young, C., Basco, R., Lamba, M., Wells, F., Ankala, R., Dowdle, W. E., Lin, A., Egenberger, K., Rukstalis, J. M., Millman, J. R., Connolly, A. J., Deuse, T., & Schrepfer, S. (2023). Human hypoimmune primary pancreatic islets avoid rejection and autoimmunity and alleviate diabetes in allogeneic humanized mice. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.adg5794
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.